- Home
- XBIO vs ATXG Comparison
XBIO vs ATXG Comparison
Compare XBIO & ATXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIO
- ATXG
- Stock Information
- Founded
- XBIO N/A
- ATXG 2014
- Country
- XBIO United States
- ATXG China
- Employees
- XBIO N/A
- ATXG N/A
- Industry
- XBIO Biotechnology: Pharmaceutical Preparations
- ATXG Professional Services
- Sector
- XBIO Health Care
- ATXG Consumer Discretionary
- Exchange
- XBIO Nasdaq
- ATXG Nasdaq
- Market Cap
- XBIO 5.8M
- ATXG 5.4M
- IPO Year
- XBIO N/A
- ATXG N/A
- Fundamental
- Price
- XBIO $2.72
- ATXG $0.65
- Analyst Decision
- XBIO Hold
- ATXG
- Analyst Count
- XBIO 1
- ATXG 0
- Target Price
- XBIO N/A
- ATXG N/A
- AVG Volume (30 Days)
- XBIO 9.9K
- ATXG 12.6K
- Earning Date
- XBIO 05-08-2025
- ATXG 02-14-2025
- Dividend Yield
- XBIO N/A
- ATXG N/A
- EPS Growth
- XBIO N/A
- ATXG N/A
- EPS
- XBIO N/A
- ATXG N/A
- Revenue
- XBIO $2,500,284.00
- ATXG $4,549,310.00
- Revenue This Year
- XBIO $14.23
- ATXG N/A
- Revenue Next Year
- XBIO N/A
- ATXG N/A
- P/E Ratio
- XBIO N/A
- ATXG N/A
- Revenue Growth
- XBIO N/A
- ATXG N/A
- 52 Week Low
- XBIO $2.20
- ATXG $0.49
- 52 Week High
- XBIO $5.20
- ATXG $1.18
- Technical
- Relative Strength Index (RSI)
- XBIO 48.09
- ATXG 43.73
- Support Level
- XBIO $2.32
- ATXG $0.60
- Resistance Level
- XBIO $2.61
- ATXG $0.70
- Average True Range (ATR)
- XBIO 0.15
- ATXG 0.09
- MACD
- XBIO 0.07
- ATXG 0.00
- Stochastic Oscillator
- XBIO 99.83
- ATXG 33.55
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.
About ATXG Addentax Group Corp.
Addentax Group Corp is an investment holding company. The company through its operating subsidiaries functions in the following segments; Garment manufacturing; Logistics services; Property management and subleasing. It generates maximum revenue from the Logistics services segment which provides logistics services including storage, transportation, warehousing, handling, packaging, and order processing. It also provides customs declaration and tax clearance services to its customers who export goods overseas. Geographically, the company derives all of its revenue from China.